Form 4: Amphastar Pharmaceuticals Director Reports Stock Sale and Equity Grants Under 10b5-1 Plan

Amphastar Pharmaceuticals, Inc. Director Floyd F. Petersen reported the sale of 500 shares of common stock and the acquisition of 5,122 restricted stock units and 11,402 stock options on June 2, 2025.

Summary

• Amphastar Pharmaceuticals, Inc. Director Floyd F. Petersen reported transactions on June 2, 2025.
• Mr. Petersen sold 500 shares of common stock at a weighted average price of $25.6701 per share, with prices ranging from $25.39 to $25.97.
• This sale was executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• Following the sale, Mr. Petersen directly beneficially owns 72,909 shares of common stock.
• Mr. Petersen also acquired 5,122 restricted stock units (RSUs) at a price of $0, which are scheduled to vest on June 2, 2026.
• Additionally, he acquired 11,402 stock options with an exercise price of $25.38, which also vest on June 2, 2026, and expire on June 2, 2035.
• After these transactions, Mr. Petersen directly beneficially owns 78,031 shares of common stock (including RSUs) and 11,402 stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there is a sale of shares, it's under a pre-planned 10b5-1 program, which mitigates negative interpretations. The significant grants of RSUs and stock options are positive as they align the director's interests with long-term shareholder value and represent ongoing compensation.

Positives

• The acquisition of 5,122 restricted stock units (RSUs) and 11,402 stock options indicates ongoing equity-based compensation for the director, aligning his interests with shareholders.
• The vesting schedule for RSUs and stock options on June 2, 2026, provides a future incentive for the director's continued performance.

Negatives

• The sale of 500 shares of common stock by a director, even if pre-planned, reduces their direct ownership in the company.

Future Outlook

The document indicates future vesting of restricted stock units and stock options on June 2, 2026, which represents future equity compensation for the director.

Industry Context

This Form 4 filing details routine insider transactions for a director at Amphastar Pharmaceuticals, Inc., a pharmaceutical company. Such filings are common across all industries for publicly traded companies and reflect standard compensation practices and pre-planned trading activities by executives and directors.

Related Party Transactions

• The transactions involve a director of Amphastar Pharmaceuticals, Inc. and the company's securities, which are inherently related-party dealings in the context of compensation and insider trading.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived negatively, but its execution under a 10b5-1 plan suggests it's not based on new, undisclosed negative information. The equity grants align the director's interests with shareholder value over the long term.
• Employees: No direct impact mentioned.

Next Steps

• The restricted stock units and stock options granted on June 2, 2025, are scheduled to vest on June 2, 2026.

Key Dates

Recommendation

Keywords

Amphastar Pharmaceuticals, AMPH, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Stock Options, Director Compensation, Rule 10b5-1 Plan, Equity Compensation